

[Pyridostigmine](#)

Essential medicine status

Section:

[20. Muscle relaxants \(peripherally-acting\) and cholinesterase inhibitors](#)

ATC codes: [N07AA02](#)

EMLc

Indication

Myasthenia gravis ICD11 code: [8C70.Z](#)

INN

Pyridostigmine bromide

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)

Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1993 ([TRS 850](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Pyridostigmine](#)

DrugBank

[Pyridostigmine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of pyridostigmine injection 1 mg in 1 mL ampoule; - the addition of pyridostigmine injection 5 mg/mL in ampoule or vial - to modify the formulation descriptions to better describe the available dosage forms.